Longevity Supplements: What the Science Actually Shows in 2025

The gap between what supplement marketing promises and what clinical science supports is enormous. The core problem is the translation gap: the majority of compounds that extend lifespan in model organisms — mice, nematodes, fruit flies — fail to replicate meaningfully in humans. Mice are short-lived (2-3 years), inbred, housed in controlled lab environments, and have fundamentally different metabolic rates and immune systems compared to genetically diverse humans living 80+ years in varied environments. A drug that adds 20% to a mouse lifespan is not evidence of anything comparable in people.

There is also a critical distinction between association and causation that supplement marketing routinely obscures. Observational data showing that people with higher blood levels of a compound live longer does not prove the compound causes longevity — it may simply reflect that healthier people with better diets and genetics naturally produce or consume more of it. This is the Bradford Hill criteria problem: correlation is not causation, and in nutrition and supplement science, confounding variables are pervasive.

Understanding the evidence hierarchy matters. In ascending order of reliability: animal study < single observational human study < randomised controlled trial (RCT) < systematic review or meta-analysis of RCTs. Most longevity supplements sit at the animal study or early observational human data level. Very few have completed phase III RCTs in humans. The supplement industry, unlike pharmaceutical drugs, requires no pre-market proof of efficacy in the US or UK — manufacturers only need to demonstrate reasonable safety. This means compounds can be sold with compelling mechanism stories and animal data without ever having been tested in humans at all.

Being a sophisticated consumer means asking: what level of evidence exists, in which population, at what dose, and for what outcome? "Activates SIRT1 in vitro" and "extends human lifespan" are not the same claim. Most longevity supplements have compelling mechanistic stories; far fewer have compelling human data.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in hundreds of cellular processes, including sirtuin activation, PARP-mediated DNA repair, and mitochondrial electron transport chain function. Blood and tissue NAD+ levels decline by approximately 50% between the ages of 40 and 60 in humans — a decline that correlates with reduced mitochondrial function, impaired DNA repair capacity, and a range of age-associated metabolic changes. This decline is the biological rationale behind NAD+ precursor supplementation. Read more about the science of NAD+ and ageing.

The two main oral NAD+ precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). NMN is one step closer to NAD+ in the biosynthesis pathway and requires a transporter (Slc12a8) to enter cells; NR enters cells more directly. A landmark 2021 Washington University School of Medicine study (Yoshino et al.) published in Science demonstrated that 250mg/day NMN for 10 weeks increased skeletal muscle NAD+ levels and improved insulin sensitivity in postmenopausal women with prediabetes. NR studies, including work by Charles Brenner's lab, consistently show that NR raises blood NAD+ metabolites, but functional benefits in healthy humans have been more modest and variable.

Harvard professor David Sinclair's advocacy for NMN has been enormously influential, though it has also attracted criticism for outpacing peer-reviewed evidence — particularly his personal claims about biological age reversal. The controversy reflects a genuine tension: the mechanistic case for NAD+ support is scientifically solid, but extrapolating from "raises NAD+" to "slows aging in humans" requires leap of faith that the evidence does not yet support. Current assessment: NMN at 250-500mg daily is reasonably safe, reliably raises NAD+ in humans, and likely supports energy metabolism and DNA repair. Proof of lifespan extension in humans is not yet available.

Few supplements have fallen further from scientific grace than resveratrol. The story begins with David Sinclair's early 2000s research at Harvard showing resveratrol activated SIRT1 (a sirtuin longevity gene) and extended lifespan in yeast, worms, and obese mice. GlaxoSmithKline acquired Sirtris Pharmaceuticals — the company Sinclair co-founded around this research — for $720 million in 2008. The expectation was that resveratrol or its derivatives would become blockbuster anti-aging drugs.

What followed was one of science's most expensive failures. Multiple large clinical trials failed to demonstrate meaningful health benefits in humans. GlaxoSmithKline's SRT501 program was terminated after clinical data proved consistently disappointing. A 2022 systematic review and meta-analysis covering 43 randomised controlled trials found no consistent benefit of resveratrol supplementation on cardiovascular risk factors, inflammatory markers, or metabolic parameters in humans. The fundamental problem is bioavailability: resveratrol is rapidly absorbed but even more rapidly metabolised, resulting in very low plasma concentrations from oral supplementation, and the concentrations required to activate SIRT1 in vitro are essentially unachievable in human tissues through oral supplementation.

The current scientific consensus is that isolated resveratrol supplements are largely ineffective at the doses available. However, this does not mean polyphenols are worthless — it means isolated single compounds at pharmaceutical doses rarely replicate the effects of whole-food dietary patterns. The Mediterranean diet, rich in dark berries, red grapes, olive oil, and legumes, delivers resveratrol alongside hundreds of other polyphenols in more bioavailable food matrices. The cardiovascular and longevity benefits seen in Mediterranean diet RCTs (including PREDIMED) are almost certainly driven by the totality of this dietary pattern rather than any single compound within it.

Coenzyme Q10 (CoQ10), also called ubiquinone, is a fat-soluble antioxidant produced endogenously that plays a critical role in the mitochondrial electron transport chain. CoQ10 production declines with age and is also significantly depleted by statin medications, which inhibit the same HMG-CoA reductase pathway used to synthesise CoQ10. The strongest human clinical evidence comes from the Q-SYMBIO trial (2014), a double-blind RCT of 420 patients with severe heart failure: those randomised to 300mg CoQ10 daily showed a 43% reduction in major adverse cardiovascular events and a 42% reduction in all-cause mortality at 2 years compared to placebo. This is one of the strongest trial results in the supplement literature. Read more about CoQ10 and mitochondrial supplements explained.

For healthy individuals over 40 or statin users, 200-400mg of ubiquinol (the reduced, active form) daily is a reasonable evidence-based supplement. Ubiquinol is preferred over standard ubiquinone for those over 40, as the enzymatic conversion from ubiquinone to ubiquinol becomes less efficient with age. CoQ10 must be taken with a fat-containing meal to ensure absorption.

Spermidine is a polyamine naturally found in wheat germ, aged cheese, soy products, and mushrooms that induces autophagy — the cellular self-cleaning process that degrades damaged organelles and proteins and declines with age. Human observational data from the InCHIANTI cohort study found that higher dietary spermidine intake was associated with lower all-cause mortality, with the highest tertile showing approximately a 5-year longer life expectancy in one analysis. The PD3-RCT — a randomised trial of spermidine-rich plant extract in older adults at risk of cognitive decline — showed significant improvements in memory performance at 12 months. Supplement doses typically provide 1.2mg of spermidine daily, though dietary sources (wheat germ delivers approximately 3mg per 100g) may achieve similar or higher intake at lower cost.

These are not over-the-counter supplements — they are prescription pharmaceuticals with genuine risk profiles and require medical supervision. But no serious discussion of longevity compounds in 2025 can ignore them, as they represent the strongest mechanistic and clinical evidence we have for pharmacological lifespan extension in mammals. For the broader biological context of why these drugs work, see our guide on caloric restriction, mTOR, and longevity.

Rapamycin is an mTOR (mechanistic target of rapamycin) inhibitor originally developed as an immunosuppressant for organ transplant recipients. In a landmark 2009 study by the National Institute on Aging, rapamycin extended median lifespan by 9-14% in mice even when treatment began at 20 months of age — the equivalent of starting a longevity drug in a 60-year-old human. This "late life" extension result is particularly compelling because it suggests reversibility of aging trajectories. Off-label use in healthy humans has grown substantially, with longevity physicians typically prescribing weekly pulsed dosing (e.g., 5-10mg once weekly) rather than daily dosing to reduce immunosuppressive effects while potentially preserving anti-aging benefits. See our detailed guide on rapamycin as a longevity drug. Risks include immunosuppression (increased infection susceptibility), impaired wound healing, dyslipidaemia, and mouth sores. None of these effects have been rigorously characterised at the pulsed dosing regimens used in longevity medicine.

Metformin, the world's most-prescribed diabetes medication, has generated extraordinary interest since observational data showed that type 2 diabetics on metformin lived longer than matched non-diabetic controls not taking any diabetes medication — suggesting the drug was doing something beyond glucose management. Metformin activates AMPK (AMP-activated protein kinase), a master cellular energy sensor that inhibits mTOR, activates autophagy, and improves mitochondrial efficiency. The TAME (Targeting Aging with Metformin) trial is the first FDA-approved clinical trial using aging itself as an endpoint, currently enrolling approximately 3,000 participants aged 65-79 across 14 US sites. One important caution: the MILES trial found that metformin at 1700mg/day partially blunted exercise-induced adaptation in healthy older adults, suggesting potential interactions with training responses that require careful consideration in active individuals.

For someone who wants to act on the best available evidence without chasing speculative compounds, a tiered approach based on evidence quality and risk profile is most sensible. Before spending money on NMN, spermidine, or other cutting-edge longevity compounds, ensure the following foundational supplements are addressed — they have far stronger evidence profiles and address deficiencies that are genuinely common in Western populations.

1. Vitamin D3 + K2: Vitamin D deficiency affects an estimated 40-50% of people in Northern Europe and North America, and correcting this deficiency has strong observational evidence for reduced all-cause mortality, cardiovascular risk, and cancer incidence. The VITAL trial (25,000 participants) found vitamin D3 supplementation at 2000 IU/day reduced cancer mortality by 25% in those who developed cancer. K2 (menaquinone-7) directs calcium appropriately to bone rather than arterial walls, making the combination particularly relevant for cardiovascular health. Dose: 2000-5000 IU vitamin D3 daily with 100-200mcg K2.

2. Omega-3 (EPA + DHA): Long-chain omega-3 fatty acids have among the largest evidence bases of any supplement, with confirmed benefits for triglyceride reduction, inflammation, and cardiovascular outcomes. The VITAL trial confirmed a significant reduction in major cardiac events with 1g/day of marine omega-3. Higher doses (2-4g/day of combined EPA+DHA) are used therapeutically for triglyceride reduction and have anti-inflammatory effects relevant to aging. Quality matters substantially — look for products tested for oxidation and heavy metal contamination.

3. Magnesium glycinate: Magnesium is a cofactor in over 300 enzymatic reactions, including ATP synthesis, DNA repair, protein synthesis, and muscle and nerve function. Surveys consistently find that 50-60% of adults in Western countries consume less than the recommended daily intake through diet alone. Magnesium deficiency is associated with higher all-cause mortality, impaired sleep quality, increased cardiovascular risk, and impaired mitochondrial function. Magnesium glycinate is the best-absorbed form with least gastrointestinal side effects. Dose: 300-400mg elemental magnesium at night (also supports sleep). 4. CoQ10/ubiquinol at 200-400mg completes the core foundational stack, particularly for those over 50 or taking statins. These four supplements address near-universal deficiencies or well-documented age-related declines before anything more speculative is considered.